Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells

Patent metadata

Field	Value
Publication number	US-2016115448-A1
Application number	US-201514922110-A
Country	US
Kind code	A1
Filing date	Oct 23, 2015
Priority date	Apr 26, 2013
Publication date	Apr 28, 2016
Grant date	—

Abstract

Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening.

First claim

1 . (canceled)

2 . (canceled)

3 . An in vitro method for generating neurons through differentiation of human pluripotent or multipotent cells, said neurons comprising one or more markers indicating a preoptic cholinergic neuron, a pre-optic cholinergic neuron precursor, a cortical interneuron, a cortical interneuron precursor, a hypothalamic neuron or a hypothalamic neuron precursor, the method comprising:
a. contacting one or more starting cells selected from the group consisting of pluripotent cells, multipotent cells and mixtures thereof with at least one and preferably two inhibitors of SMAD and with at least one Wnt antagonist to favor generation of neuronal precursors from said pluripotent or multipotent cells or mixtures thereof; b. after the passage of a predetermined period of time, contacting the neuronal precursors with at least one activator of SHH signaling to favor generation from said precursors of neurons having at least one marker indicating a pre-optic cholinergic neuron, a pre-optic cholinergic neuron precursor, a cortical interneuron, a cortical interneuron precursor, a hypothalamic neuron or a hypothalamic neuron precursor; and c. optionally subjecting said generated pre-optic cholinergic neurons or pre-optic cholinergic neuron precursors, cortical interneurons, cortical interneuron precursors, hypothalamic neurons or hypothalamic neuron precursors to conditions favoring their maturation.

4 . The method of claim 3 wherein said one or more starting cells are human or murine.

5 . (canceled)

6 . The method of claim 3 wherein said one or more starting cells comprise at least one class of cells selected from the group consisting of embryonic stem cells, adult stem cells, neural stem cells, induced pluripotent cells, engineered pluripotent cells, primary progenitor cells, induced progenitor cells, and engineered progenitor cells.

7 . The method of claim 3 wherein said contacting with the at least one SMAD inhibitor and said contacting with the Writ signaling antagonist is carried out simultaneously or sequentially and each has a duration between about 5 days and about 30 days.

8 . The method of claim 3 , wherein said at least one SMAD signaling inhibitor is selected from the group consisting of SB431542, LDN-193189, Noggin PD169316, SB203580, LY364947, A77-01, A-83-01, BMP4, GW788388, GW6604, SB-505124, lerdelimumab, metelimumab, GC-I008, AP-12009, AP-110I4, LY550410, LY580276, LY364947, LY2109761, SB-505124, E-616452 (RepSox ALK inhibitor), SD-208, SMI6, NPC-30345, KÏ26894, SB-203580, SD-093, activin-M108A, P144, soluble TBR2-Fc, DMH-1, Dorsomorphin dihydrochloride and derivatives thereof.

9 . The method of claim 8 wherein the SMAD signaling inhibitor comprises SB431542 and LDN-193189.

10 . The method of claim 9 wherein
(i) SB431542 is provided at a concentration within the range between about 0.1 μM and about 1 mM in a culture medium containing said cells;
(ii) SB431542 is provided at a concentration within the range between about 0.1 μM and about 100 μM in a culture medium containing said cells;
(iii) LDN-193189 is provided at a concentration within the range between about 1 nM and about 10 μM in a culture medium containing said cells;
(iv) LDN-193189 is provided at a concentration within the range between about 1 nM and about 1 μM in a culture medium containing said cells;
or a combination thereof.

11 . (canceled)

12 . The method of claim 3 wherein the Wnt antagonist is selected from the group consisting of XAV939, DKK1, DKK-2, DKK-3, Dkk-4, SFRP-1, SFRP-2, SFRP-5, SFRP-3, SFRP-4, WIF-1, Soggy, IWP-2, IWR1, ICG-001, KY0211, Wnt-059, LGK974, IWP-L6 and derivatives thereof.

13 . (canceled)

14 . The method of claim 12 wherein
(i) XAV939 is provided at a concentration within the range between about 10 nM and about 500 μM in a culture medium containing said cells; or
(ii) XAV939 is provided at a concentration within the range between about 0.2 μM and about 200 μM in a culture medium containing said cells.

15 . The method of claim 3 wherein said at least one activator of SHH signaling is selected from the group consisting of Smoothened agonist (SAG), SAG analog, SHH, C25-SHH, C24-SHH, purmorphamine, Hg—Ag and derivatives thereof.

16 . The method of claim 15 wherein said at least one activator of SHH signaling comprises both recombinant SHH and purmorphamine.

17 . The method of claim 16 wherein recombinant SHH is provided at a concentration within the range between about 5 ng/mL and about 5 μg/mL in a culture medium containing said cells, purmorphamine is provided at a concentration within the range between about 0.1 μM and about 20 μM in a culture medium containing said cells, or a combination thereof.

18 . (canceled)

19 . The method of claim 3 , wherein said neuron comprises one or more markers indicating a cortical interneuron or a cortical interneuron precursor, and wherein
(i) step (b) is initiated at least 4 and up to 20 days after initiation of the step (a); (ii) step (b) is concluded from about 5 to about 30 days after its initiation; (iii) step (b) is initiated between about 8 and about 18 days after initiation of the step (a) and concluded between about 8 and about 16 days after initiation of the step (b); (iv) step (b) is initiated at least 6 and up to 20 days after initiation of the step (a); or (v) step (b) is initiated at least 8 and up to 18 days after initiation of the step (a).

20 . (canceled)

21 . (canceled)

22 . The method of claim 3 , wherein said one or more markers indicating a cortical interneuron are selected from the group consisting of SST, PV, GAB A, calbindin, LHX6, RAX, FOXA2, FOXG1, OLIG2, NKX6.2, VGLUT1, MAP2, CTIP2, SATB2, TBR1, DLX2, ASCL1, ChAT and combinations thereof.

23 . The method of claim 3 , wherein said neuron comprises one or more markers indicating a hypothalamic neuron or a hypothalamic neuron precursor, and wherein
step (b) is initiated at least 1 and up to 4 days after initiation of the step (a); step (b) is concluded from about 5 to about 30 days after its initiation; or step (b) is initiated between about 1 and about 4 days after initiation of the step (a) and concluded between about 8 and about 20 days after initiation of the step (b).

24 . (canceled)

25 . (canceled)

26 . The method of claim 3 , wherein said one or more markers indicating a hypothalamic neuron are selected from the group consisting of NGFI-B, c-fos, CRF, tyrosine hydroxylase (TH), RAX, POMC, hypocretin, NADPH and combinations thereof.

27 . The method of claim 3 , wherein said neuron comprises one or more markers indicating a preoptic cholinergic neuron or a pre-optic cholinergic neuron precursor, wherein
step (b) is initiated at least 4 and up to 10 days after initiation of the step (a); step (b) is concluded from about 5 to about 30 days after its initiation; or step (b) is initiated between about 4 and about 8 days after initiation of the step (a) and concluded between about 8 and about 24 days after initiation of the step (b).

28 . (canceled)

29 . (canceled)

30 . The method of claim 3 , wherein said one or more markers indicating a preoptic cholinergic neuron are selected from the group consisting of ChAT, NGF, Ach, VAChT, LHX8, 1, p75 and combinations thereof.

31 . The method of claim 3 wherein

Assignees

• Sloan Kettering Inst Cancer
• Univ Cornell

Inventors

• Studer Lorenz
• Maroof Asif M
• Anderson Stewart

Classifications

• C12N2506/02

  from embryonic cells · CPC title

• C12N2501/999

  Small molecules not provided for elsewhere · CPC title

• C12N2502/08

  cells of the nervous system · CPC title

• C12N2501/415

  Wnt; Frizzeled · CPC title

• C12N5/0619 Primary

  Neurons · CPC title